Designing vaccine candidates against dengue virus by in silico studies on structural and nonstructural domains.


Journal

Molecular and cellular probes
ISSN: 1096-1194
Titre abrégé: Mol Cell Probes
Pays: England
ID NLM: 8709751

Informations de publication

Date de publication:
06 2022
Historique:
received: 14 01 2022
revised: 06 04 2022
accepted: 18 04 2022
pubmed: 25 4 2022
medline: 10 5 2022
entrez: 24 4 2022
Statut: ppublish

Résumé

One-third of the world's population is at risk of Dengue infection. Envelope domain 3 (EDIII) and nonstructural protein1 (NS1) proteins as the potent antigenicity regions for humoral immunity in addition to the bc loop region as a completely conserved region have been used for designing protective vaccines. We aimed to design vaccine candidates according to the bc loop, EDIII, and NS1 regions of Dengue serotype2 to be used as vaccine candidates for all serotypes of Dengue virus especially serotype 2. Firstly the bc loop region with EDII fragments at both ends as well as EDIII and NS1 regions were used which were linked with the GGGGS linker to the bc loop region. In two other strategies, the bc loop with EDII and NS1 fragments at both ends was used to increase its structural stability. Tertiary structure prediction and validation of vaccine constructs indicated that all vaccine constructs were modeled with high quality and stable structure during molecular dynamics simulation. B cell epitope mapping by Bepipred and ElliPro methods confirmed the existence of high potent epitopes in the bc loop, EDIII, and NS1 regions in both linear and conformational B cell epitopes. Furthermore, molecular docking for the bc loop region demonstrated that all designed vaccines have a higher affinity to interact with 1C19 monoclonal antibody than only the bc loop region or bc loop epitope in the protein EII. Our data of in silico studies indicated that the designed vaccines could effectively induce humoral immunity against four dengue serotypes.

Identifiants

pubmed: 35461964
pii: S0890-8508(22)00029-9
doi: 10.1016/j.mcp.2022.101818
pii:
doi:

Substances chimiques

Antibodies, Viral 0
Epitopes, B-Lymphocyte 0
Vaccines 0
Viral Envelope Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101818

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Auteurs

Mohammad Shoushtari (M)

Department of Virology, Pasteur Institute of Iran, Tehran, Iran.

Ladan Mafakher (L)

Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.

Saman Rahmati (S)

Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.

Mostafa Salehi-Vaziri (M)

Department of Arboviruses and Viral Hemorrhagic Fevers National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran.

Arash Arashkia (A)

Department of Virology, Pasteur Institute of Iran, Tehran, Iran.

Farzin Roohvand (F)

Department of Virology, Pasteur Institute of Iran, Tehran, Iran.

Ladan Teimoori-Toolabi (L)

Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. Electronic address: lteimoori@pasteur.ac.ir.

Kayhan Azadmanesh (K)

Department of Virology, Pasteur Institute of Iran, Tehran, Iran. Electronic address: azadmanesh@pasteur.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH